A HIGHER ASPIRATION IN CANCER THERAPY.
We are developing differentiated radiopharmaceutical therapies (RPT) for some of the most difficult-to-treat cancers. Our growing pipeline includes novel RPT agents and companion diagnostic assets with the potential to provide curative responses for patients with advanced disease.
OUR LEADERSHIP
TEAM
Evan has a PhD in medical physics and an MBA from the University of Wisconsin and has spent his career developing new technologies in nuclear medicine. He was formerly the president of Phoenix, a company developing particle accelerator technologies with applications in healthcare, energy, and defense. There he focused primarily on new technology and business development and financing, and both revenue and headcount at the company grew by >20X during his 10-year tenure. Evan helped lead the successful sale of Phoenix to SHINE Technologies in 2021 and subsequently served as the general manager of SHINE’s Phoenix Division and then as SHINE’s Chief Business Development Officer. He joined Archeus as CEO in 2022 and is focused on advancing its cancer-targeting agents into human clinical trials.
Zach is an associate professor and chair of the Department of Human Oncology at the University of Wisconsin. He is a Rhodes Scholar and completed an MD/PhD at Harvard’s Biological and Biomedical Sciences Program. Zach is a practicing physician with a clinical focus on the treatment of patients with melanoma and soft tissue sarcomas. He leads an independent translational research lab at UW-Madison focused on novel treatment approaches utilizing targeted radioisotope therapies. He is an active member of several professional societies and has an extensive publication record. He is actively involved in preclinical research with Archeus’ cancer-targeting agents and is leading the design and oversight of the company’s planned clinical trials.
In addition to serving as Archeus' Chief Technology Officer, Reinier is an assistant professor of medical physics at the University of Wisconsin. He is a radiochemist with research interests focused on theranostics, targeted radionuclide therapy, and radio-immuno-oncology. He is the recipient of numerous academic awards, has an extensive publication record, and is the inventor on multiple patents for cancer treatment and imaging agents. He has a proven track record of designing novel cancer targeting agents and taking them from concept through in vitro and in vivo preclinical testing and into clinical translation. He has extensive experience developing and implementing diagnostic and therapeutic radiolabeling and radioanalytical methods using a broad range of isotopes in preclinical and clinical settings.
Dave is the founder of Casimir Jones, an intellectual property law firm. He has a JD from Stanford and a PhD in biochemistry from the University of Wisconsin. As an actively practicing IP attorney, he focuses on patent prosecution, post-issuance proceedings, litigation, litigation avoidance, due diligence, business counseling, and licensing with an emphasis in biotechnology, pharmaceuticals, chemicals, and medical devices. He has participated in the prosecution of over a thousand patent applications, many of which focus on cancer therapies, including targeted radionuclide therapy. He has significant experience and expertise in managing large, complex patent portfolios and positioning such portfolios for withstanding scrutiny in litigation and due diligence analysis associated with funding or acquisition events.
Jon Ohrn is the founder of PharmaShares Advisors and is currently an advisor at Rockefeller Capital Management. He previously spent four years with SVB Leerink as Managing Director, Mergers and Acquisitions. Before that, he spent 13-years at Deutsche Bank, most recently serving as a Managing Director of the Americas Mergers & Acquisitions team. Jon specializes in structuring extremely complex transactions involving tax matters, cross border situations and other forms of intricate consideration. Throughout his career, he has advised clients on numerous deals across industry sectors including media and entertainment and technology, with more than $50 billion in healthcare transactions to his credit.
Howard is a professor of medicine and the associate dean for oncology at the University of Wisconsin School of Medicine and Public Health and is the director of the University of Wisconsin Carbone Cancer Center. He is board certified in internal medicine and medical oncology, and his clinical practice focuses on the treatment of sarcomas and gynecologic malignancies. His research focuses on anti-cancer drug development, especially chemoprevention. Howard is the principal investigator of the UW Chemoprevention Consortium, an NCI-sponsored research network of universities that conduct Phase I and II clinical trials for chemopreventative agents. He has directed or participated in more than 100 clinical trials for cancer prevention and treatment, and he serves on the national committee which reviews all NCI-designated cancer centers.
Bruce Berndt is the Founder and CEO of Berndt CPA LLC, a Madison-based firm specializing in serving Entrepreneurs and funded start-ups through outsourced accounting, tax, payroll, and HR services. Under his leadership, the firm has achieved recognition as an Inc. 5000 company and has been honored as a top workplace in the accounting industry. With over four decades of experience, Bruce previously served as Regional Managing Partner at Clifton Gunderson LLP (CLA), where he oversaw multiple offices and was a firm board member. He serves on the Advisory Board of Capitol Bank and is actively involved with several Dane County nonprofits. He holds a Bachelor of Business Administration in Accounting from the University of Wisconsin Oshkosh.
Evan has a PhD in medical physics and an MBA from the University of Wisconsin and has spent his career developing new technologies in nuclear medicine. He was formerly the president of Phoenix, a company developing particle accelerator technologies with applications in healthcare, energy, and defense. There he focused primarily on new technology and business development and financing, and both revenue and headcount at the company grew by >20X during his 10-year tenure. Evan helped lead the successful sale of Phoenix to SHINE Technologies in 2021 and subsequently served as the general manager of SHINE’s Phoenix Division and then as SHINE’s Chief Business Development Officer. He joined Archeus as CEO in 2022 and is focused on advancing its cancer-targeting agents into human clinical trials.
Zach is an associate professor and chair of the Department of Human Oncology at the University of Wisconsin. He is a Rhodes Scholar and completed an MD/PhD at Harvard’s Biological and Biomedical Sciences Program. Zach is a practicing physician with a clinical focus on the treatment of patients with melanoma and soft tissue sarcomas. He leads an independent translational research lab at UW-Madison focused on novel treatment approaches utilizing targeted radioisotope therapies. He is an active member of several professional societies and has an extensive publication record. He is actively involved in preclinical research with Archeus’ cancer-targeting agents and is leading the design and oversight of the company’s planned clinical trials.
In addition to serving as Archeus' Chief Technology Officer, Reinier is an assistant professor of medical physics at the University of Wisconsin. He is a radiochemist with research interests focused on theranostics, targeted radionuclide therapy, and radio-immuno-oncology. He is the recipient of numerous academic awards, has an extensive publication record, and is the inventor on multiple patents for cancer treatment and imaging agents. He has a proven track record of designing novel cancer targeting agents and taking them from concept through in vitro and in vivo preclinical testing and into clinical translation. He has extensive experience developing and implementing diagnostic and therapeutic radiolabeling and radioanalytical methods using a broad range of isotopes in preclinical and clinical settings.
Dave is the founder of Casimir Jones, an intellectual property law firm. He has a JD from Stanford and a PhD in biochemistry from the University of Wisconsin. As an actively practicing IP attorney, he focuses on patent prosecution, post-issuance proceedings, litigation, litigation avoidance, due diligence, business counseling, and licensing with an emphasis in biotechnology, pharmaceuticals, chemicals, and medical devices. He has participated in the prosecution of over a thousand patent applications, many of which focus on cancer therapies, including targeted radionuclide therapy. He has significant experience and expertise in managing large, complex patent portfolios and positioning such portfolios for withstanding scrutiny in litigation and due diligence analysis associated with funding or acquisition events.
Jon Ohrn is the founder of PharmaShares Advisors and is currently an advisor at Rockefeller Capital Management. He previously spent four years with SVB Leerink as Managing Director, Mergers and Acquisitions. Before that, he spent 13-years at Deutsche Bank, most recently serving as a Managing Director of the Americas Mergers & Acquisitions team. Jon specializes in structuring extremely complex transactions involving tax matters, cross border situations and other forms of intricate consideration. Throughout his career, he has advised clients on numerous deals across industry sectors including media and entertainment and technology, with more than $50 billion in healthcare transactions to his credit.
Howard is a professor of medicine and the associate dean for oncology at the University of Wisconsin School of Medicine and Public Health and is the director of the University of Wisconsin Carbone Cancer Center. He is board certified in internal medicine and medical oncology, and his clinical practice focuses on the treatment of sarcomas and gynecologic malignancies. His research focuses on anti-cancer drug development, especially chemoprevention. Howard is the principal investigator of the UW Chemoprevention Consortium, an NCI-sponsored research network of universities that conduct Phase I and II clinical trials for chemopreventative agents. He has directed or participated in more than 100 clinical trials for cancer prevention and treatment, and he serves on the national committee which reviews all NCI-designated cancer centers.
Bruce Berndt is the Founder and CEO of Berndt CPA LLC, a Madison-based firm specializing in serving Entrepreneurs and funded start-ups through outsourced accounting, tax, payroll, and HR services. Under his leadership, the firm has achieved recognition as an Inc. 5000 company and has been honored as a top workplace in the accounting industry. With over four decades of experience, Bruce previously served as Regional Managing Partner at Clifton Gunderson LLP (CLA), where he oversaw multiple offices and was a firm board member. He serves on the Advisory Board of Capitol Bank and is actively involved with several Dane County nonprofits. He holds a Bachelor of Business Administration in Accounting from the University of Wisconsin Oshkosh.
OUR ADVISORS
Norman is the chief medical officer and senior VP at Plus Therapeutics. He was previously chief medical officer and Senior VP at Jubilant Pharma, responsible for all pharma medical & regulatory affairs activities. Prior to Jubilant, he served as global chief medical officer at IBA Molecular and as senior VP, clinical development and chief medical officer at Molecular Insight Pharmaceuticals. Prior to industry, Norman practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is double board certified with fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the US along with active professional society memberships.
Jamey is a co-founder of Archeus and a professor of radiology at the University of Wisconsin with affiliate appointments in medical physics and pharmaceutics. He has a PhD in Medicinal Chemistry from the University of Michigan. He established UW-Madison’s Small Animal Imaging and Radiotherapy Facility and currently serves as its faculty director. Jamey is the lead scientist responsible for developing several of Archeus’ pipeline cancer imaging and therapy agents. He currently oversees a large research group that is responsible for much of the preclinical work underlying Archeus’ technologies, with focus areas in cancer-targeted molecular contrast agents, PET and CT imaging, and targeted radionuclide therapy. He has over 80 peer reviewed publications, is the co-inventor on more than 50 patents, and is the principal investigator on several major NIH grant programs. At Archeus, Jamey is responsible for scientific oversight of all preclinical research and pipeline development activities.
Jeremie is professor and director of the Clinical Research Program at UCLA’s Ahmanson Translational Theranostics Division, and a faculty member at the Jonsson Comprehensive Cancer Center and the Institute of Urologic Oncology. A leading researcher in prostate cancer imaging and theranostics, he serves as principal investigator of randomized Phase 2 and Phase 3 trials in PSMA PET imaging and PSMA radionuclide therapy. The Ahmanson Translational Theranostics Division submitted, jointly with UCSF, the academic NDA for ⁶⁸Ga-PSMA-11 — the first FDA-approved PSMA PET imaging agent for prostate cancer. Jeremie received his MD from the University of Paris-Diderot and is board-certified in nuclear medicine in France.
Lawrence is scientific director of the Immunotherapy Integrated Research Center at Fred Hutch Cancer Center. A physician-scientist focused on cancer immunotherapy, Lawrence has contributed to the development of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors, and led clinical trials combining immune checkpoint inhibitors with radiopharmaceuticals including radium-223 and PSMA-lutetium-177. He is a recipient of the National Cancer Institute Outstanding Investigator Award and received his MD and completed his fellowship in medical oncology at Stanford University.
Marco is the owner of Gottardis Biotech LLC, a biopharmaceutical consultancy, and previously served as vice president of oncology innovation at Janssen Pharmaceuticals (Johnson & Johnson). He spent nine years leading Janssen’s prostate cancer research and development portfolio as vice president and prostate cancer program leader, and 14 years prior in oncology discovery research at Bristol Myers Squibb. He has led teams responsible for advancing development candidates from IND through Phase 2 proof of concept, and contributed to multiple FDA-approved therapies. Marco holds a BS in Biology from Columbia University and a PhD in Human Oncology from the University of Wisconsin–Madison.
Jonathan most recently served as chief scientific officer of WARF Therapeutics, the Wisconsin Alumni Research Foundation’s drug discovery program. During his eight-year tenure, his team reviewed more than 60 University of Wisconsin–Madison research opportunities and advanced three development candidates to licensing, including WT-7695 (now SKL37321), a CA9 radiopharmaceutical licensed to SK Biopharmaceuticals in November 2025. Earlier, Jonathan held senior chemistry leadership roles at Regulus Therapeutics, Celgene, and Merck Research Laboratories. He received his PhD in Chemistry from Michigan State University.
Stuart is professor of oncology at the Johns Hopkins Kimmel Cancer Center. For the past 22 years, he has served as principal investigator and director of Central Operations for the National Cancer Institute-funded Phase 1/2 brain tumor consortia, including the Adult Brain Tumor Consortium. Stuart has led many Phase 1, 2, and 3 translational and clinical brain cancer research projects, with expertise in designing and directing large, multicenter, multidisciplinary clinical trial groups. He received his MD from the University of Rochester School of Medicine and completed his fellowship in medical oncology at the Johns Hopkins University School of Medicine.
Norman is the chief medical officer and senior VP at Plus Therapeutics. He was previously chief medical officer and Senior VP at Jubilant Pharma, responsible for all pharma medical & regulatory affairs activities. Prior to Jubilant, he served as global chief medical officer at IBA Molecular and as senior VP, clinical development and chief medical officer at Molecular Insight Pharmaceuticals. Prior to industry, Norman practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is double board certified with fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the US along with active professional society memberships.
Jamey is a co-founder of Archeus and a professor of radiology at the University of Wisconsin with affiliate appointments in medical physics and pharmaceutics. He has a PhD in Medicinal Chemistry from the University of Michigan. He established UW-Madison’s Small Animal Imaging and Radiotherapy Facility and currently serves as its faculty director. Jamey is the lead scientist responsible for developing several of Archeus’ pipeline cancer imaging and therapy agents. He currently oversees a large research group that is responsible for much of the preclinical work underlying Archeus’ technologies, with focus areas in cancer-targeted molecular contrast agents, PET and CT imaging, and targeted radionuclide therapy. He has over 80 peer reviewed publications, is the co-inventor on more than 50 patents, and is the principal investigator on several major NIH grant programs. At Archeus, Jamey is responsible for scientific oversight of all preclinical research and pipeline development activities.
Jeremie is professor and director of the Clinical Research Program at UCLA’s Ahmanson Translational Theranostics Division, and a faculty member at the Jonsson Comprehensive Cancer Center and the Institute of Urologic Oncology. A leading researcher in prostate cancer imaging and theranostics, he serves as principal investigator of randomized Phase 2 and Phase 3 trials in PSMA PET imaging and PSMA radionuclide therapy. The Ahmanson Translational Theranostics Division submitted, jointly with UCSF, the academic NDA for ⁶⁸Ga-PSMA-11 — the first FDA-approved PSMA PET imaging agent for prostate cancer. Jeremie received his MD from the University of Paris-Diderot and is board-certified in nuclear medicine in France.
Lawrence is scientific director of the Immunotherapy Integrated Research Center at Fred Hutch Cancer Center. A physician-scientist focused on cancer immunotherapy, Lawrence has contributed to the development of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors, and led clinical trials combining immune checkpoint inhibitors with radiopharmaceuticals including radium-223 and PSMA-lutetium-177. He is a recipient of the National Cancer Institute Outstanding Investigator Award and received his MD and completed his fellowship in medical oncology at Stanford University.
Marco is the owner of Gottardis Biotech LLC, a biopharmaceutical consultancy, and previously served as vice president of oncology innovation at Janssen Pharmaceuticals (Johnson & Johnson). He spent nine years leading Janssen’s prostate cancer research and development portfolio as vice president and prostate cancer program leader, and 14 years prior in oncology discovery research at Bristol Myers Squibb. He has led teams responsible for advancing development candidates from IND through Phase 2 proof of concept, and contributed to multiple FDA-approved therapies. Marco holds a BS in Biology from Columbia University and a PhD in Human Oncology from the University of Wisconsin–Madison.
Jonathan most recently served as chief scientific officer of WARF Therapeutics, the Wisconsin Alumni Research Foundation’s drug discovery program. During his eight-year tenure, his team reviewed more than 60 University of Wisconsin–Madison research opportunities and advanced three development candidates to licensing, including WT-7695 (now SKL37321), a CA9 radiopharmaceutical licensed to SK Biopharmaceuticals in November 2025. Earlier, Jonathan held senior chemistry leadership roles at Regulus Therapeutics, Celgene, and Merck Research Laboratories. He received his PhD in Chemistry from Michigan State University.
Stuart is professor of oncology at the Johns Hopkins Kimmel Cancer Center. For the past 22 years, he has served as principal investigator and director of Central Operations for the National Cancer Institute-funded Phase 1/2 brain tumor consortia, including the Adult Brain Tumor Consortium. Stuart has led many Phase 1, 2, and 3 translational and clinical brain cancer research projects, with expertise in designing and directing large, multicenter, multidisciplinary clinical trial groups. He received his MD from the University of Rochester School of Medicine and completed his fellowship in medical oncology at the Johns Hopkins University School of Medicine.
OUR PUBLICATIONS
.jpg)
.jpg)
.jpg)
.jpg)
RECENT NEWS
Archeus Technologies Reconstitutes Advisory Board to Advance Clinical-Stage Radiopharmaceutical Pipeline
ReadArcheus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer
ReadArcheus Technologies Expands Leadership to Advance Portfolio of Small-Molecule Radiopharmaceutical Therapies
ReadWANT TO
GET IN TOUCH?
WANT TO
GET IN TOUCH?